The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?
| Autor: | Martina Schüßler-Lenz, Mohamed Abou-El-Enein, Silke Schüle, Toni Cathomen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Gene Editing Genome Human Perspective (graphical) Racial Groups Bioengineering 02 engineering and technology Genetic Therapy 021001 nanoscience & nanotechnology Europe 03 medical and health sciences Race (biology) 030104 developmental biology Genome editing Preclinical testing CRISPR Humans Human genome Engineering ethics 0210 nano-technology Risk assessment Psychology Drug Approval Biotechnology |
| Zdroj: | Trends in biotechnology. 37(2) |
| ISSN: | 1879-3096 |
| Popis: | Medicinal products based on genome editing must undergo rigorous preclinical testing and are subject to regulatory oversight for proper risk assessment prior to first evaluation in humans. We give a European perspective on the regulatory expectations to translate genome editing to the clinic to ensure their timely progress to market. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect